T2 Biosystms Net Worth
T2 Biosystms Net Worth Breakdown | TTOO |
T2 Biosystms Net Worth Analysis
T2 Biosystms' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including T2 Biosystms' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of T2 Biosystms' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform T2 Biosystms' net worth analysis. One common approach is to calculate T2 Biosystms' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares T2 Biosystms' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing T2 Biosystms' net worth. This approach calculates the present value of T2 Biosystms' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of T2 Biosystms' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate T2 Biosystms' net worth. This involves comparing T2 Biosystms' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into T2 Biosystms' net worth relative to its peers.
Enterprise Value |
|
To determine if T2 Biosystms is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding T2 Biosystms' net worth research are outlined below:
| T2 Biosystms generated a negative expected return over the last 90 days | |
| T2 Biosystms has high historical volatility and very poor performance | |
| T2 Biosystms has some characteristics of a very speculative penny stock | |
| T2 Biosystms has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.19 M. Net Loss for the year was (50.08 M) with loss before overhead, payroll, taxes, and interest of (24.77 M). | |
| T2 Biosystms currently holds about 13.21 M in cash with (48.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| T2 Biosystms has a frail financial position based on the latest SEC disclosures | |
| Roughly 74.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Epicore Biosystems Named to Fast Companys Fourth Annual List of the Next Big Things in Tech |
T2 Biosystms uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in T2 Biosystms. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to T2 Biosystms' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 11th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Know T2 Biosystms' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as T2 Biosystms is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading T2 Biosystms backward and forwards among themselves. T2 Biosystms' institutional investor refers to the entity that pools money to purchase T2 Biosystms' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Cwm, Llc Duplicate | 2024-06-30 | 310 | Advisor Group Holdings, Inc. | 2024-06-30 | 205 | Bank Of America Corp | 2024-06-30 | 128 | International Assets Investment Management, Llc | 2024-09-30 | 65.0 | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 28.0 | Jpmorgan Chase & Co | 2024-06-30 | 15.0 | Jjj Advisors Inc | 2024-06-30 | 9.0 | U.s. Bancorp | 2024-06-30 | 3.0 | Ubs Group Ag | 2024-06-30 | 1.0 | Armistice Capital, Llc | 2024-09-30 | 1.4 M | Vanguard Group Inc | 2024-09-30 | 390.4 K |
Follow T2 Biosystms' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 10.31 M.Market Cap |
|
Project T2 Biosystms' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.44) | (1.51) | |
| Return On Capital Employed | 2.33 | 2.44 | |
| Return On Assets | (1.44) | (1.51) | |
| Return On Equity | 1.79 | 1.88 |
When accessing T2 Biosystms' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures T2 Biosystms' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of T2 Biosystms' profitability and make more informed investment decisions.
Evaluate T2 Biosystms' management efficiency
T2 Biosystms has return on total asset (ROA) of (0.9046) % which means that it has lost $0.9046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.2214) %, meaning that it created substantial loss on money invested by shareholders. T2 Biosystms' management efficiency ratios could be used to measure how well T2 Biosystms manages its routine affairs as well as how well it operates its assets and liabilities. At this time, T2 Biosystms' Return On Capital Employed is very stable compared to the past year. As of the 26th of November 2024, Return On Equity is likely to grow to 1.88, while Return On Tangible Assets are likely to drop (1.51). At this time, T2 Biosystms' Total Assets are very stable compared to the past year. As of the 26th of November 2024, Non Current Assets Total is likely to grow to about 11.6 M, while Non Currrent Assets Other are likely to drop about 345.7 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (10.74) | (11.28) | |
| Tangible Book Value Per Share | (10.74) | (11.28) | |
| Enterprise Value Over EBITDA | (1.14) | (1.20) | |
| Price Book Value Ratio | (0.58) | (0.56) | |
| Enterprise Value Multiple | (1.14) | (1.20) | |
| Price Fair Value | (0.58) | (0.56) | |
| Enterprise Value | 57.7 M | 75.5 M |
The management team at T2 Biosystms has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 3.5394 | Revenue 7.2 M | Quarterly Revenue Growth (0.01) | Revenue Per Share 0.999 | Return On Equity (6.22) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific T2 Biosystms insiders, such as employees or executives, is commonly permitted as long as it does not rely on T2 Biosystms' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases T2 Biosystms insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
T2 Biosystms time-series forecasting models is one of many T2 Biosystms' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary T2 Biosystms' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
T2 Biosystms Earnings per Share Projection vs Actual
T2 Biosystms Corporate Management
| Roger Smith | Senior Development | Profile | |
| Aparna MD | Chief Board | Profile | |
| Kelley Morgan | Chief Officer | Profile | |
| Michael Esq | Sr Counsel | Profile | |
| Brett Giffin | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in T2 Biosystms. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in TTOO Stock, please use our How to Invest in T2 Biosystms guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of T2 Biosystms. If investors know TTOO will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about T2 Biosystms listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.03) | Revenue Per Share 0.999 | Quarterly Revenue Growth (0.01) | Return On Assets (0.90) | Return On Equity (6.22) |
The market value of T2 Biosystms is measured differently than its book value, which is the value of TTOO that is recorded on the company's balance sheet. Investors also form their own opinion of T2 Biosystms' value that differs from its market value or its book value, called intrinsic value, which is T2 Biosystms' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because T2 Biosystms' market value can be influenced by many factors that don't directly affect T2 Biosystms' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between T2 Biosystms' value and its price as these two are different measures arrived at by different means. Investors typically determine if T2 Biosystms is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, T2 Biosystms' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.